The novel extended-release formulation is expected to prevent both acute and delayed CINV for up to 5 days, improving patient compliance and convenience.

Although chemotherapy helps kill cancer cells, it can also affect healthy white blood cells, weakening the immune system. Eating nutritious foods, exercising, and avoiding illnesses are some ways to ...

Amid a shortage of standard-of-care chemotherapy drugs, Sagent Pharmaceuticals is pulling two lots of its docetaxel injection from U.S. shelves after receiving a report of potential particulate matter ...

Incyte (NASDAQ: INCY) and Enable Injections have formed a strategic partnership to co-develop and commercialize targeted cancer therapies using Enable’s enFuse® On-Body Delivery System, ...

Shilpa Medicare Announces Positive Phase 3 Results for OERIS™ — A Novel Once-Weekly Ondansetron Extended-Release Injection ...